Back to search

Peptide record

TPDB13092

Antibacterial Antiviral Hemolysis Toxicity standard
18 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB13092
Antibacterial Antiviral Hemolysis Toxicity
Anti-infective peptides Toxicity and safety peptides
AntiBP3 Peptipedia AI4AVP dbAMP 3.0 PD_Hemolysis
standard
No
A 18-aa standard natural multi-activity (Antibacterial, Antiviral, Hemolysis, and other sources) peptide sequence curated from AntiBP3, Peptipedia, AI4AVP, and other sources, with an available 3D structural model.
Sequence
FLFSLIRKAIGGLISAFK
Physicochemical Analysis
C97H157N23O21
NDCEQHMPTWYV
ILF
1981.45
11.64
3
0
11
+3
-3.27
1.233
141.11
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
0
0.00
2
Residue Composition
number
2
A
1
R
0
N
0
D
0
C
0
E
0
Q
2
G
0
H
3
I
3
L
2
K
0
M
3
F
0
P
2
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 2 R: 1 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 2 H: 0 I: 3 L: 3 K: 2 M: 0 F: 3 P: 0 S: 2 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
18
C97H157N23O21
1981.45
11.64
+3
-3.27
1.233
Evidence Records 21 records
Evidence 1 Activity

Activity

MIC
Antibacterial
32 µg/mL

Target

A. baumannii ATCC 19606

Source & Reference

NA

Other

active against E.coli ATCC 25922 (MIC> 256 ug/ml), A. baumannii ATCC 19606 (MIC 32 ug/ml), K.pneumoniae ATCC BAA-1705 (MIC > 256 ug/ml), E.cloacae ATCC 700323 (MIC >256 ug/ml), P.
Evidence 2 Activity

Activity

MIC
Antibacterial
>256 µg/mL

Target

E.cloacae ATCC 700323

Source & Reference

NA

Other

l), A. baumannii ATCC 19606 (MIC 32 ug/ml), K.pneumoniae ATCC BAA-1705 (MIC > 256 ug/ml), E.cloacae ATCC 700323 (MIC >256 ug/ml), P.aeruginosa ATCC 27853 (MIC > 256 ug/ml), S. aureus MSSA ATCC 25923 (MIC 8 ug/ml).
Evidence 3 Activity

Activity

MIC
Antibacterial
8 µg/mL

Target

Staphylococcus aureus MSSA ATCC 25923

Source & Reference

NA

Other

g/ml), E.cloacae ATCC 700323 (MIC >256 ug/ml), P.aeruginosa ATCC 27853 (MIC > 256 ug/ml), S. aureus MSSA ATCC 25923 (MIC 8 ug/ml).
Evidence 4 Activity

Activity

MIC
Antiviral
32 µg/mL

Target

A. baumannii ATCC 19606

Source & Reference

dbAMP 3.0

Other

Source Activity Label Source Definition
Antiviral
dbAMP 3.0 classified under the Anti-viral function class.
active against E.coli ATCC 25922 (MIC> 256 ug/ml), A. baumannii ATCC 19606 (MIC 32 ug/ml), K.pneumoniae ATCC BAA-1705 (MIC > 256 ug/ml), E.cloacae ATCC 700323 (MIC >256 ug/ml), P.
Evidence 5 Activity

Activity

MIC
Antiviral
>256 µg/mL

Target

E.cloacae ATCC 700323

Source & Reference

dbAMP 3.0

Other

l), A. baumannii ATCC 19606 (MIC 32 ug/ml), K.pneumoniae ATCC BAA-1705 (MIC > 256 ug/ml), E.cloacae ATCC 700323 (MIC >256 ug/ml), P.aeruginosa ATCC 27853 (MIC > 256 ug/ml), S. aureus MSSA ATCC 25923 (MIC 8 ug/ml).
Evidence 6 Activity

Activity

MIC
Antiviral
8 µg/mL

Target

Staphylococcus aureus MSSA ATCC 25923

Source & Reference

dbAMP 3.0

Other

g/ml), E.cloacae ATCC 700323 (MIC >256 ug/ml), P.aeruginosa ATCC 27853 (MIC > 256 ug/ml), S. aureus MSSA ATCC 25923 (MIC 8 ug/ml).
Evidence 7 Activity

Activity

IC50
Toxicity
33.2 µM
Cytotoxic
IC50 | 33.2 | µM | target cell: Human embryonic kidney HEK293 cells

Target

Human embryonic kidney HEK293 cells

Source & Reference

NA
DBAASP
A3, a Scorpion Venom Derived Peptide Analogue with Potent Antimicrobial and Potential Antibiofilm Activity against Clinical Isolates of Multi-Drug Resistant Gram Positive Bacteria. | Molecules | 2018
Evidence 8 Activity

Activity

IC50
Toxicity
26.1 µM
Cytotoxic
IC50 | 26.1 | µM | target cell: Vero cells

Target

Vero cells

Source & Reference

NA
DBAASP
A3, a Scorpion Venom Derived Peptide Analogue with Potent Antimicrobial and Potential Antibiofilm Activity against Clinical Isolates of Multi-Drug Resistant Gram Positive Bacteria. | Molecules | 2018
Evidence 9 Activity

Activity

49.4% Hemolysis
Toxicity
80 µM
Hemolytic Cytotoxic
49.4% Hemolysis | 80 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
A3, a Scorpion Venom Derived Peptide Analogue with Potent Antimicrobial and Potential Antibiofilm Activity against Clinical Isolates of Multi-Drug Resistant Gram Positive Bacteria. | Molecules | 2018
Evidence 10 Activity

Activity

47.9% Hemolysis
Toxicity
60 µM
Hemolytic Cytotoxic
47.9% Hemolysis | 60 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
A3, a Scorpion Venom Derived Peptide Analogue with Potent Antimicrobial and Potential Antibiofilm Activity against Clinical Isolates of Multi-Drug Resistant Gram Positive Bacteria. | Molecules | 2018
Evidence 11 Activity

Activity

36.1% Hemolysis
Toxicity
40 µM
Hemolytic Cytotoxic
36.1% Hemolysis | 40 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
A3, a Scorpion Venom Derived Peptide Analogue with Potent Antimicrobial and Potential Antibiofilm Activity against Clinical Isolates of Multi-Drug Resistant Gram Positive Bacteria. | Molecules | 2018
Evidence 12 Activity

Activity

16.8% Hemolysis
Toxicity
20 µM
Hemolytic Cytotoxic
16.8% Hemolysis | 20 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
A3, a Scorpion Venom Derived Peptide Analogue with Potent Antimicrobial and Potential Antibiofilm Activity against Clinical Isolates of Multi-Drug Resistant Gram Positive Bacteria. | Molecules | 2018
Evidence 13 Activity

Activity

5.1% Hemolysis
Toxicity
10 µM
Hemolytic Cytotoxic
5.1% Hemolysis | 10 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
A3, a Scorpion Venom Derived Peptide Analogue with Potent Antimicrobial and Potential Antibiofilm Activity against Clinical Isolates of Multi-Drug Resistant Gram Positive Bacteria. | Molecules | 2018
Evidence 14 Activity

Activity

0% Hemolysis
Toxicity
1-5 µM
Hemolytic Cytotoxic
0% Hemolysis | 1-5 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
A3, a Scorpion Venom Derived Peptide Analogue with Potent Antimicrobial and Potential Antibiofilm Activity against Clinical Isolates of Multi-Drug Resistant Gram Positive Bacteria. | Molecules | 2018
Evidence 15 Activity

Activity

10% Hemolysis
Toxicity
9 µg/mL
Hemolytic Cytotoxic
10% Hemolysis | 9 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
QSAR Reveals Decreased Lipophilicity of Polar Residues Determines the Selectivity of Antimicrobial Peptide Activity. | ACS Omega | 2024
Evidence 16 Activity

Activity

50% Hemolysis
Toxicity
54 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 54 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
QSAR Reveals Decreased Lipophilicity of Polar Residues Determines the Selectivity of Antimicrobial Peptide Activity. | ACS Omega | 2024
Evidence 17 Activity

Activity

LC
Toxicity
256 µg/mL
Cytotoxic
LC | 256 | µg/mL | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
QSAR Reveals Decreased Lipophilicity of Polar Residues Determines the Selectivity of Antimicrobial Peptide Activity. | ACS Omega | 2024
Evidence 18 Activity

Activity

LC50
Toxicity
113.8 µg/mL
Cytotoxic
LC50 | 113.8 | µg/mL | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
QSAR Reveals Decreased Lipophilicity of Polar Residues Determines the Selectivity of Antimicrobial Peptide Activity. | ACS Omega | 2024
Evidence 19 Activity

Activity

10% Hemolysis
Toxicity
24 µg/mL
Hemolytic Cytotoxic
10% Hemolysis | 24 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
QSAR Reveals Decreased Lipophilicity of Polar Residues Determines the Selectivity of Antimicrobial Peptide Activity. | ACS Omega | 2024
Evidence 20 Activity

Activity

50% Hemolysis
Toxicity
78 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 78 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
QSAR Reveals Decreased Lipophilicity of Polar Residues Determines the Selectivity of Antimicrobial Peptide Activity. | ACS Omega | 2024
Evidence 21 Hemolysis

Source & Reference

PD_Hemolysis
PD_Hemolysis